Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Items 201–370 of 370
Calcium and Vitamin D Supplementation Increases Spinal BMD in Healthy, Postmenopausal Women
Bæksgaard, L., Andersen, K. P., & Hyldstrup, L. (1998) · Osteoporosis International · doi:10.1007/s001980050062 · Cited by 127
The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid
Grbic, J. T., Black, D. M., Lyles, K. W., Reid, D. M., ORWOLL, E. S., McClung, M. R., Bucci-Rechtweg, C. M., & Su, G. (2010) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2010.0082 · Cited by 126
Quandt, S. A., Thompson, D. E., Schneider, D. L., Nevitt, M. C., & Black, D. M. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.3.343 · Cited by 125 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialGreenspan, S. L., Schneider, D. L., McClung, M. R., Miller, P. D., Schnitzer, T. J., Bonin, R., Smith, M. E., DeLucca, P., Gormley, G. J., & Melton, M. E. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-10-200205210-00009 · Cited by 124 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialManchikanti, L., Singh, V., Cash, K. A., Pampati, V., Damron, K. S., & Boswell, M. V. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/273 · Cited by 121
Gallagher, J. C., Riggs, B. L., Recker, R. R., & Goldgar, D. (1989) · Experimental Biology and Medicine · doi:10.3181/00379727-191-42922 · Cited by 119
Bell, K., Hayen, A. D., Macaskill, P., Irwig, L., Craig, J. C., Ensrud, K. E., & Bauer, D. C. (2009) · BMJ · doi:10.1136/bmj.b2266 · Cited by 119 · cited 1×
“Data from 1 study (365) showed that only 10% of women with normal or mildly osteopenic DXA scores (T score > –1.”
BackgroundTreatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation
Torres, A., García, S., Gćmez, A., González, A., Barrios, Y., Concepción, M. T., Hernández, D., García, J. J., Checa, M. D., de Lorenzo, V., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00432.x · Cited by 118
McClung, M., Miller, P., Recknor, C., Mesenbrink, P., Bucci-Rechtweg, C., & Benhamou, C.-L. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181bdce0a · Cited by 117
Eastell, R., Black, D. M., Boonen, S., Adami, S., Felsenberg, D., Lippuner, K., Cummings, S. R., Delmas, P. D., Palermo, L., Mesenbrink, P., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2765 · Cited by 116
Risedronate Prevents New Vertebral Fractures in Postmenopausal Women at High Risk
Watts, N. B., Josse, R. G., Hamdy, R. C., Hughes, R. A., Manhart, M. D., Barton, I., Calligeros, D., & Felsenberg, D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020400 · Cited by 115 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRinge, J. D., Dorst, A., Faber, H., & Ibach, K. (2004) · Rheumatology International · doi:10.1007/s00296-003-0388-y · Cited by 113 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialJansen, J. P., Bergman, G., Huels, J., & Olson, M. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.06.001 · Cited by 113
Nationwide Survey for Bisphosphonate-Related Osteonecrosis of the Jaws in Japan
Urade, M., Tanaka, N., Furusawa, K., Shimada, J., Shibata, T., Kirita, T., Yamamoto, T., Ikebe, T., Kitagawa, Y., & Fukuta, J. (2011) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2011.03.051 · Cited by 113
Mosca, L., Grady, D., Barrett-Connor, E., Collins, P., Wenger, N., Abramson, B. L., Paganini-Hill, A., Geiger, M. J., Dowsett, S. A., Amewou-Atisso, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.518621 · Cited by 112 · cited 1×
“92) (122, 341, 345, 347) and cerebrovascular death (OR, 1.”
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene
McClung, M. R., Siris, E., Cummings, S., Bolognese, M., Ettinger, M., Moffett, A., Emkey, R., Day, W., Somayaji, V., & Lee, A. (2006) · Menopause · doi:10.1097/01.gme.0000188736.69617.4f · Cited by 111
Kanis, J. А., Johansson, H., Odén, A., & McCloskey, E. V. (2010) · Bone · doi:10.1016/j.bone.2010.06.009 · Cited by 109 · cited 2×
“One post hoc analysis of a trial with raloxifene showed that treatment efficacy did not vary according to FRAX score (241), and at age 75 years, the risk reduction for vertebral fracture was similar across FRAX scores.”
MethodPrevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years
Jolly, E. E., Bjarnason, N. H., Neven, P., Plouffe, Johnston, Watts, S. D., Arnaud, C. D., Mason, T. M., Crans, G., Akers, R., et al. (2003) · Menopause · doi:10.1097/01.gme.0000058772.59606.2a · Cited by 107
Cranney, A., Wells, G. A., Yetisir, E., Adámi, S., Cooper, C. C., Delmas, P. D., Miller, P. D., Papapoulos, S. E., Reginster, J., Sambrook, P. N., et al. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0653-8 · Cited by 107
Hopkins, R. B., Goeree, R. A., Pullenayegum, E., Adachi, J. D., Παπαϊωάννου, Α., Xie, F., & Thabane, L. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-209 · Cited by 104
Fractal geometry and vertebral compression fractures
Weinstein, R. S., & Majumdar, S. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091117 · Cited by 101
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis
Seeman, E., Crans, G. G., Díez‐Pérez, A., Pinette, K. V., & Delmas, P. D. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2030-1 · Cited by 100
Milgrom, C., Finestone, A. S., Novack, V., Pereg, D., Goldich, Y., Kreiss, Y., Zimlichman, E., Kaufman, S., Liebergall, M., & Burr, D. B. (2004) · Bone · doi:10.1016/j.bone.2004.04.016 · Cited by 98 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRinge, J. D., Farahmand, P., Faber, H., & Dorst, A. (2008) · Rheumatology International · doi:10.1007/s00296-008-0689-2 · Cited by 98 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialCalcitonin, Etidronate, and Calcidiol Treatment in Bone Loss after Cardiac Transplantation
Garcia-Delgado, I., Prieto, S., Gil-Fraguas, L., Robles, E., Rufilanchas, J. J., & Hawkins, F. G. (1997) · Calcified Tissue International · doi:10.1007/s002239900206 · Cited by 97
Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls
O’Donnell, S. C., Moher, D., Thomas, K., Hanley, D. A., & Cranney, A. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0868-y · Cited by 97
Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene
Meunier, P. J., Vignot, E., Garnero, P., Confavreux, E., Paris, E., Liu-Léage, S., Sarkar, S., Liu, T., Wong, M., & Draper, M. W. (1999) · Osteoporosis International · doi:10.1007/s001980050236 · Cited by 96
HANSSON, T. H., & ROOS, B. (1987) · Calcified Tissue International · doi:10.1007/bf02556692 · Cited by 94
Palacios, S., Silverman, S. L., de Villiers, T. J., Levine, A. B., Goemaere, S., Brown, J. P., De Cicco Nardone, F., Williams, R., Hines, T. L., Mirkin, S., et al. (2015) · Menopause · doi:10.1097/gme.0000000000000419 · Cited by 93
Repeat Bone Mineral Density Screening and Prediction of Hip and Major Osteoporotic Fracture
Berry, S. D., Samelson, E. J., Pencina, M. J., McLean, R. R., Cupples, L. A., Broe, K. E., & Kiel, D. P. (2013) · JAMA · doi:10.1001/jama.2013.277817 · Cited by 91 · cited 1×
“Another study showed no improvement in prediction of hip or major fractures in women who had BMD measured 4 years after baseline (357).”
BackgroundSelf-citationAnti-Hip Fracture Efficacy of Bisphosphonates: A Bayesian Analysis of Clinical Trials
Nguyen, N. D., Eisman, J. A., & Nguyen, T. V. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050903 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialHosking, D., Adami, S., Felsenberg, D., Andia, J. C., Välimäki, M., Benhamou, L., Reginster, J.-Y., Yacik, C., Rybak-Feglin, A., Petruschke, R. A., et al. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002009 · Cited by 89 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialHarris, S. T., Watts, N. B., Li, Z., Chines, A. A., Hanley, D. A., & Brown, J. P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003566 · Cited by 88 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialAvenell, A., Grant, A. M., McGee, M., McPherson, G., Campbell, M. K., McGee, M. A., & RECORD Trial Management Group (2004) · Clinical Trials · doi:10.1191/1740774504cn053oa · Cited by 87
Ascott-Evans, B. H., Guañabens, N., Kivinen, S., Stuckey, B. G. A., Magaril, C., Vandormael, K., Stych, B., & Melton, M. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.7.789 · Cited by 86 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialEtminan, M., Forooghian, F., & Maberley, D. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.111752 · Cited by 84
O’Ryan, F., & Lo, J. C.-M. (2012) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2011.08.033 · Cited by 84
Greenspan, S. L., Beck, T., Resnick, N. M., Bhattacharya, R. K., & Parker, R. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050508 · Cited by 81
A model for involutional bone loss.
Aloia, J. F., Vaswani, A. N., Ellis, K. A., Yuen, K., & Sh, C. (1985) · PubMed · Cited by 80
SHIRAKI, M., KUSHIDA, K., YAMAZAKI, K., NAGAI, T., INOUE, T., & ORIMO, H. (1996) · Endocrine Journal · doi:10.1507/endocrj.43.211 · Cited by 79
Lifestyle interventions to prevent osteoporotic fractures: a systematic review
Lock, C. A., Lecouturier, J., Mason, J. M., & Dickinson, H. O. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1942-0 · Cited by 79
Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A., Netelenbos, C., Watts, N. B., Seeman, E., Ciaccia, A. V., & Draper, M. W. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.8.871 · Cited by 79
Pazianas, M., Abrahamsen, B., Eiken, P., Eastell, R., & Russell, R. G. G. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1902-4 · Cited by 79
Bonnick, S., Broy, S., Kaiser, F., Teutsch, C., Rosenberg, E., DeLucca, P., & Melton, M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188035 · Cited by 79
Lai, J. K. C., Lucas, R. M., Clements, M. S., Roddam, A. W., & Banks, E. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-331 · Cited by 79
Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3179-x · Cited by 78
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
Siris, E. S., Simon, J. A., Barton, I. P., McClung, M. R., & Grauer, A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0493-y · Cited by 78 · cited 1×
“This evidence comes from a post hoc analysis of 2-year follow-up data from 4 large RCTs of postmenopausal women with advanced osteopenia and no prevalent vertebral fractures that showed that treatment with risedronate significantly reduced the risk for fragility fracture compared with placebo (73% lower than placebo)…”
MethodSawka, A. M., Papaioannou, A., Adachi, J. D., Gafni, A., Hanley, D. A., & Thabane, L. (2005) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-6-39 · Cited by 77 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialTennis, P. S., Rothman, K. J., Bohn, R. L., Tan, H., Zavras, A. I., Laskarides, C., Calingaert, B., & Anthony, M. S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3292 · Cited by 77
Ringe, J. D., Farahmand, P., Schacht, E., & Rozehnal, A. (2007) · Rheumatology International · doi:10.1007/s00296-006-0288-z · Cited by 77 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialClemmesen, B., Ravn, P., Zegels, B., Taquet, A. N., Christiansen, C., & Reginster, J.-Y. (1997) · Osteoporosis International · doi:10.1007/pl00004152 · Cited by 76 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBisphosphonate adverse effects, lessons from large databases
Abrahamsen, B. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833ad677 · Cited by 73
Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial
Bischoff-Ferrari, H. A., Rees, J. R., Grau, M. V., Barry, E. L., Gui, J., & Baron, J. A. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.6.1945 · Cited by 73
Uchida, S., Taniguchi, T., Shimizu, T., Kakikawa, T., Okuyama, K., Okaniwa, M., Arizono, H., Nagata, K., Santora, A. C., Shiraki, M., et al. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0616-5 · Cited by 72
Stakkestad, J. A., Benevolenskaya, L. I., Stepan, J. J., Skag, A., Nordby, A., Oefjord, E., Burdeska, A., Jonkanski, I., & Mahoney, P. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.10.969 · Cited by 72 · cited 1×
“29]) (92, 310), and zoledronic acid is associated with adverse effects including atrial fibrillation (OR, 1.”
BackgroundLong-term Outcomes of Exercise: Follow-up of a Randomized Trial in Older Women With Osteopenia
Korpelainen, R., Keinänen-Kiukaanniemi, S., Nieminen, P., Heikkinen, J., Väänänen, K., & Korpelainen, J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.311 · Cited by 67
Exposure to oral bisphosphonates and risk of cancer
Cardwell, C. R., Abnet, C. C., Veal, P., Hughes, C. M., Cantwell, M. M., & Murray, L. (2011) · International Journal of Cancer · doi:10.1002/ijc.27389 · Cited by 67
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results
Delmas, P. D., Benhamou, C. L., Man, Z., Tłustochowicz, W., Matzkin, E., Eusebio, R. A., Zanchetta, J., Olszynski, W. P., Recker, R. R., & McClung, M. R. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0531-9 · Cited by 67 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialVinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2013) · BMJ · doi:10.1136/bmj.f114 · Cited by 65
Solomon, D. H., Mercer, E., Woo, S. B., Avorn, J., Schneeweiß, S., & Treister, N. S. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2042-6 · Cited by 65
For the MOVER Study Group, Nakamura, T., Nakano, T., Ito, M., Hagino, H., Hashimoto, J., Tobinai, M., & Mizunuma, H. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9734-6 · Cited by 65
Prevrhal, S., Krege, J. H., Chen, P., Genant, H. K., & Black, D. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902790993 · Cited by 64 · cited 1×
“Moderate-quality evidence from post hoc analysis of 1 RCT showed that postmenopausal women with prevalent vertebral fractures benefited more from teriparatide treatment than those without prevalent fractures (245).”
BackgroundIncreased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab
Toulis, K. A., & Anastasilakis, A. D. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1145-1 · Cited by 63
Tauchmanovà, L., SIMONE, G. D., Musella, T., Orio, F., Ricci, P., Nappi, C., Lombardi, G., Colao, A. A. L., Rotoli, B., & Selleri, C. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705196 · Cited by 62
A Meta-Analysis of High Dose, Intermittent Vitamin D Supplementation among Older Adults
Zheng, Y. T., Cui, Q. Q., Hong, Y. M., & Yao, W. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115850 · Cited by 62
Efficacy of vitamin D 3 supplementation in preventing fractures in elderly women: A meta-analysis
Bergman, G. J. D., Fan, T., McFetridge, J. T., & Sen, S. S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003659814 · Cited by 62
Sugimoto, T., Matsumoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Fukunaga, M., Sone, T., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2964-2 · Cited by 62 · cited 1×
“One Japanese trial and its 1-year open-label extension study included postmenopausal osteoporotic women with prevalent radiographic vertebral fractures and showed that denosumab protected against radiographic vertebral fractures (101, 109).”
BackgroundVestergaard, P., Jørgensen, N. R., Mosekilde, L., & Schwarz, P. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0204-0 · Cited by 61
Effect of Raloxifene on Cardiovascular Adverse Events in Postmenopausal Women With Osteoporosis
Ensrud, K. E., Genazzani, A. R., Geiger, M. J., McNabb, M. A., Dowsett, S. A., Cox, D. A., & Barrett-Connor, E. L. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.083 · Cited by 61
OKADA, Y., NAWATA, M., NAKAYAMADA, S., SAITO, K., & TANAKA, Y. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080168 · Cited by 60
Exercise therapy for osteoporosis: results of a randomised controlled trial.
Preisinger, E., Alacamlioglu, Y., Pils, K., Bosina, E., Metka, M., Schneider, B., & Ernst, E. (1996) · British Journal of Sports Medicine · doi:10.1136/bjsm.30.3.209 · Cited by 59
A Case Study of Discordant Overlapping Meta-Analyses: Vitamin D Supplements and Fracture
Bolland, M. J., & Grey, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115934 · Cited by 59
Freitas, M. D., López-Cedrún, J., Sanromán, J. F., García, A. G., Feijoo, J. F., & Dios, P. D. (2012) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.18041 · Cited by 58
Fahrleitner-Pammer, A., Piswanger-Soelkner, J. C., Pieber, T. R., Obermayer-Pietsch, B. M., Pilz, S., Dimai, H. P., Prenner, G., Tscheliessnigg, K.-H., Hauge, E., Portugaller, R. H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090216 · Cited by 57
Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide
Miller, P. D., Bilezikian, J. P., Díaz Curiel, M., Chen, P., Marín, F., Krege, J. H., Wong, M., & Marcus, R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2439 · Cited by 57
Luckey, M., Kagan, R., Greenspan, S., Bone, H., Kiel, R. D. P., Simon, J., Sackarowitz, J., Palmisano, J., Chen, E., Petruschke, R. A., et al. (2004) · Menopause · doi:10.1097/01.gme.0000119981.77837.1f · Cited by 56
Oral bisphosphonate use in the elderly is not associated with acute kidney injury
Shih, A. W. Y., Weir, M. A., Clemens, K. K., Yao, Z., Gomes, T., Mamdani, M., Juurlink, D. N., Hird, A. E., Hodsman, A. B., Parikh, C. R., et al. (2012) · Kidney International · doi:10.1038/ki.2012.227 · Cited by 55
Boone, R. H., Cheung, A. M., Girlan, L. M., & Heathcote, E. J. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-8015-x · Cited by 54
Hooper, M. J., Ebeling, P. R., Roberts, A. P., Graham, J. J., Nicholson, G. C., D'Emden, M., Ernst, T. F., & Wenderoth, D. (2005) · Climacteric · doi:10.1080/13697130500118126 · Cited by 54 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialCOMPARISON OF ALENDRONATE, CALCITONIN AND CALCIUM TREATMENTS IN POSTMENOPAUSAL OSTEOPOROSIS
Dursun, N., Dursun, E., & Yalçin, S. (2001) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2001.tb11111.x · Cited by 53 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialLee, S.-H., Chang, S.-S., Lee, M., Chan, R., & Lee, C. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2575-3 · Cited by 53
Patel, D. V., Bolland, M. J., Nisa, Z. U., Al‐Abuwsi, F., Singh, M., Horne, A. M., Reid, I. R., & McGhee, C. N. J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2872-5 · Cited by 52 · cited 1×
“7%]) in women treated with zoledronic acid (309).”
BackgroundBarrett-Connor, E. L., Swern, A. S., Hustad, C. M., Bone, H., Liberman, U. A., Papapoulos, S. E., Wang, H., de Papp, A., & Santora, A. C. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1546-9 · Cited by 50
Kishimoto, H., Fukunaga, M., Kushida, K., Shiraki, M., Itabashi, A., Nawata, H., Nakamura, T., Ohta, H., Takaoka, K., & Ohashi, Y. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0706-z · Cited by 50 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialGreenspan, S. L., Bhattacharya, R. K., Sereika, S. M., Brufsky, A., & Vogel, V. G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1272 · Cited by 49 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialTadrous, M., Wong, L., Mamdani, M., Juurlink, D. N., Krahn, M. D., Lévesque, L. E., & Cadarette, S. M. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2576-2 · Cited by 49 · cited 1×
“High-quality evidence showed that bisphosphonates are associated with mild upper gastrointestinal symptoms (83, 291–303), and a network meta-analysis did not show statistically significant differences between the various bisphosphonates for gastrointestinal symptoms (304).”
BackgroundHansen, P. J., Knitschke, M., Draenert, F. G., Irle, S., & Neff, A. (2012) · Clinical Oral Investigations · doi:10.1007/s00784-012-0873-3 · Cited by 49
Jansen, J. P., Bergman, G. J. D., Huels, J., & Olson, M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903035281 · Cited by 47 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialMichalská, D., Stepan, J. J., Basson, B. R., & Pavo, I. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2212 · Cited by 46
Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxy-vitamin D3
Hayashi, Y., Fujita, T., & Inoue, T. (1992) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf02378983 · Cited by 46
Alfacalcidol (Alpha D3) and Calcium in Osteoporosis
MENCZEL, J., FOLDES, J., STEINBERG, R., LEICHTER, I., SHALITA, B., BDOLAH-ABRAM, T., KADOSH, S., MAZOR, Z., & LADKANI, D. (1994) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199403000-00033 · Cited by 45
FRAX and the effect of teriparatide on vertebral and non-vertebral fracture
Harvey, N. C., Kanis, J. A., Odén, A., Burge, R. T., Mitlak, B. H., Johansson, H., & McCloskey, E. V. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3173-3 · Cited by 45
Migliore, A., Broccoli, S., Massafra, U., Cassol, M., & Frediani, B. (2013) · PubMed · Cited by 45
Fracture prevention with vitamin D supplementation: considering the inconsistent results
Izaks, G. J. (2007) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-8-26 · Cited by 44
Therapeutic potential of parathyroid hormone
Cosman, F., & Lindsay, R. (2004) · Current Osteoporosis Reports · doi:10.1007/s11914-004-0008-0 · Cited by 44
Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis
Rhee, C. W., Lee, J.-S., Oh, S., Choi, N., & Park, B. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1608-z · Cited by 44
Παπαϊωάννου, Α., Kennedy, C. C., Freitag, A. P., Ioannidis, G., O'Neill, J., Webber, C. E., Pui, M. H., Berthiaume, Y., Rabin, H. R., Paterson, N. A. M., et al. (2008) · CHEST Journal · doi:10.1378/chest.08-0608 · Cited by 44 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialEfficacy and Safety of Raloxifene 60 Milligrams/Day in Postmenopausal Asian Women
Kung, A. W. C., Chao, H.-T., Huang, K.-E., Need, A. G., Taechakraichana, N., Loh, F.-H., Gonzaga, F., Sriram, U., Ismail, N. M. N., Farooqi, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021855 · Cited by 43
Does 1,25(OH)2D3 Accelerate Spinal Bone Loss?: A Controlled Therapeutic Trial in 70-year-old Women
Finn, G., Meinecke, B., Boesen, J., & TRANSBØL, I. (1985) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198501000-00030 · Cited by 43
Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF)
Chapman, I., Greville, H. W., Ebeling, P. R., King, S., Kotsimbos, T. C., Nugent, P., Player, R., Topliss, D. J., Warner, J., & Wilson, J. W. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03434.x · Cited by 43 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialHartle, J. E., Tang, X., Kirchner, H. L., Bucaloiu, I. D., Sartorius, J. A., Pogrebnaya, Z., Akers, G., Carnero, G. E., & Perkins, R. M. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.11.037 · Cited by 42
Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies
Sun, K., Liu, J. M., Sun, H. X., Lu, N., & Ning, G. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2158-8 · Cited by 41
Vestergaard, P. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9539-4 · Cited by 41
Chiang, C.-H., Huang, C., Chan, W., Huang, P., Chen, T., Chung, C., Lin, S., Chen, J., & Leu, H. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1645 · Cited by 40
Rabenda, V., Bruyère, O., & Reginster, J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1469-x · Cited by 39
Bisphosphonates and risk of atrial fibrillation: a meta-analysis
Kim, S. C., Kim, M. J., Cadarette, S. M., & Solomon, D. H. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2938 · Cited by 39
FRAX provides robust fracture prediction regardless of socioeconomic status
Brennan-Olsen, S. L., Leslie, W. D., Lix, L. M., Johansson, H., Oden, A., McCloskey, E. V., & Kanis, J. A. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2525-0 · Cited by 38
A Prospective Study of Bisphosphonate Use and Risk of Colorectal Cancer
Khalili, H., Huang, E. S., Ogino, S., Fuchs, C. S., & Chan, A. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2670 · Cited by 38
Meta‐analysis: oral bisphosphonates and the risk of oesophageal cancer
Andrici, J., Tio, M., & Eslick, G. D. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12041 · Cited by 37
Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.383 · Cited by 37
Effects of calcium supplementation on bone loss and fractures in congestive heart failure
Frost, R. J., Sonne, C., Wehr, U., & Stempfle, H. U. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0614 · Cited by 37
on behalf of the Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group, Lapi, F., Cipriani, F., Caputi, A. P., Corrao, G., Vaccheri, A., Sturkenboom, M., Bari, M. D., Gregori, D., Carle, F., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2013-y · Cited by 36
Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women
Bai, H., Jing, D., Guo, A., & Yin, S. (2013) · Journal of International Medical Research · doi:10.1177/0300060513480917 · Cited by 36 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialKumagai, Y., Hasunuma, T., & Padhi, D. (2011) · Bone · doi:10.1016/j.bone.2011.08.007 · Cited by 34
Kang, J., Keller, J. J., & Lin, H. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1894-0 · Cited by 34
Bocanegra-Perez, M., Barrero, M. V., Henríquez, M. S., Rodríguez‐Bocanegra, E., Limiñana-Cañal, J. M., Lopez-Marquez, A., Plasencia, D. P., & Macías, Á. R. (2012) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.17946 · Cited by 34
Miller, P. D., Delmas, P. D., Huss, H., Patel, K., Schimmer, R. C., Adami, S., & Recker, R. R. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9403-y · Cited by 31
The effect of bisphosphonates on the risk of endometrial and ovarian malignancies
Rennert, G., Rennert, H. S., Pinchev, M., & Lavie, O. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.014 · Cited by 31
Prevention of Low Back Pain in Sedentary Healthy Workers: A Pilot Study
Moore, C., Ceridan, E., Schonard, C., Marasa, M., Shaib, F. H., & Holland, J. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3182364942 · Cited by 30
Fujita, T., Fukunaga, M., Itabashi, A., Tsutani, K., & Nakamura, T. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9777-8 · Cited by 30
Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD With Teriparatide Treatment
Watts, N. B., Miller, P. D., Kohlmeier, L., Sebba, A. I., Chen, P., Wong, M., & Krohn, K. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081256 · Cited by 29
Myocardial Infarction Risk Among Patients With Fractures Receiving Bisphosphonates
Pittman, C. B., Davis, L. A., Zeringue, A., Caplan, L., Wehmeier, K. R., Scherrer, J. F., Xian, H., Cunningham, F. E., McDonald, J. R., Arnold, A., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.08.021 · Cited by 29
Zoledronic acid and atrial fibrillation in cancer patients
Arslan, Ç., Aksoy, S., Dızdar, Ö., Dede, D. Ş., Harputluoğlu, H., & Altundağ, K. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0868-z · Cited by 29
Nguyen, D., Schwartz, J. T., Richardson, P. A., & El‐Serag, H. B. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1198-1 · Cited by 29
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Palacios, S., Kalouche-Khalil, L., Rizzoli, R., Zapalowski, C., Resch, H., Adachi, J. D., Gallagher, J. C., Feldman, R. G., Kendler, D. L., Wang, A., et al. (2015) · Climacteric · doi:10.3109/13697137.2015.1045484 · Cited by 29
Palomba, S., Orio, F., Manguso, F., Falbo, A. I., Russo, T., Tolino, A., Tauchmanovà, L., Colao, A. A. L., Doldo, P., Mastrantonio, P., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1927-z · Cited by 28 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialGorai, I., Chaki, O., Taguchi, Y., Nakayama, M., Osada, H., SUZUKI, N., Katagiri, N., Misu, Y., & MINAGUCHI, H. (1999) · Calcified Tissue International · doi:10.1007/s002239900651 · Cited by 28
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis
Nakamura, T., Liu, J. L., Morii, H., Huang, Q., Zhu, H. M., Qu, Y., Hamaya, E., & Thiébaud, D. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0702-3 · Cited by 28 · cited 1×
“Race/Ethnicity High-quality evidence from post hoc analysis of 2 RCTs showed that compared with placebo, raloxifene decreases the relative risk for vertebral fracture but not nonvertebral or hip fracture among Asian women (250), consistent with findings from U.”
ResultOsteonecrosis of the Jaw in Older Osteoporosis Patients Treated with Intravenous Bisphosphonates
Baillargeon, J., Kuo, Y. F., Lin, Y., Wilkinson, G. S., & Goodwin, J. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q239 · Cited by 28
The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass
Xia, W., Zhang, Z., Wang, H.-F., Meng, X., Zhang, Y., Zhu, G., Xing, X., Liu, J.-L., Wang, L.-H., Jiang, Y., et al. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.12 · Cited by 27
Lee, W.-Y., Sun, L.-M., Lin, M., Liang, J., Chang, S., Sung, F.-C., Muo, C., & Kao, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053032 · Cited by 27
Wang, J., Chien, W., Chung, C., Liao, W.-I., & Tsai, S. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.088 · Cited by 26
Boonen, S., Klemes, A. B., Zhou, X., & Lindsay, R. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02763.x · Cited by 25
Bianchi, G., & Sambrook, P. N. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802370912 · Cited by 25 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialOral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer
Newcomb, P. A., Passarelli, M. N., Phipps, A. I., Anderson, G. L., Wactawski‐Wende, J., Ho, G. Y. F., O’Sullivan, M. J., & Chlebowski, R. T. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.6842 · Cited by 25
Caniggia, A., Delling, G., Nuti, R., Loré, F., & Vattimo, A. (1984) · PubMed · Cited by 25
Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases.
ALMĂŞAN, H. A., Băciuț, M. F., Rotaru, H., Bran, S., Almăşan, O. C., & Băciuț, G. (2011) · PubMed · Cited by 24
Ushiroyama, T., Ikeda, A., Sakai, M., Higashiyama, T., & Ueki, M. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00243-2 · Cited by 22
Alendronate and Risk of Esophageal Cancer: A Nationwide Population‐Based Study in T aiwan
Chen, Y., Tsai, Y., Liu, C., Chen, Y.-T., Chang, L., Huang, W., Chen, D., Hsiao, F., & Chen, L. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03693.x · Cited by 22
Muscoso, E. G., Puglisi, N., Mamazza, C., Giudice, F. L., Testaì, M., Abbate, S., Santangelo, A., Panebianco, P., & Maugeri, D. (2004) · PubMed · Cited by 20
Palomba, S., Manguso, F., Orio, F., Russo, T., Oppedisano, R., Sacchinelli, A., Falbo, A. I., Tolino, A., Zullo, F., & Mastrantonio, P. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318159f190 · Cited by 20 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialStudy on the role of zoledronic acid in treatment of postmenopausal osteoporosis
Chao, M., Hua, Q., Yingfeng, Z., Guang, W., Shufeng, S., Dong, Y., Wang, W., & Haifeng, T. (2013) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.296.3677 · Cited by 20 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialOral bisphosphonates and risk of ischemic stroke: a case–control study
Christensen, S., Mehnert, F., Chapurlat, R. D., Baron, J. A., & Sørensen, H. T. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1395-y · Cited by 20
Jung, S. Y., Sohn, H. S., Park, E.-J., Suh, H. S., Park, J. W., & Kwon, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150531 · Cited by 20
Miyauchi, A., Fujita, T., Ohue, M., Fujii, Y., & Takagi, Y. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0445-3 · Cited by 18
Kanaji, A., Higashi, M., Namisato, M., Nishio, M., Ando, K., & Yamada, H. (2006) · Leprosy Review · doi:10.47276/lr.77.2.147 · Cited by 18 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialCharacteristics of Bisphosphonate-Related Osteonecrosis of the Jaw After Kidney Transplantation
Park, W., Lee, S.-H., Park, K.-R., Rho, S.-H., Chung, W., & Kim, H. J. (2012) · Journal of Craniofacial Surgery · doi:10.1097/scs.0b013e31825b33f6 · Cited by 18
TERIPARATIDE (rhPTH 1–34) FOR THE TREATMENT OF OSTEOPOROSIS
Ebeling, P. R., & Russell, R. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10593.x · Cited by 17
Gu, J., Wang, L., Lin, H. V., Chen, D., Tang, H., Jin, X., Xia, W., Hu, Y.-Q., Fu, W., He, J., et al. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.30 · Cited by 17
Carmona, E. C., Flores, A. G., Loza, E., Olea, A. H., & Lozano, M. P. R. (2013) · Reumatología Clínica · doi:10.1016/j.reuma.2012.05.005 · Cited by 16
Benefits and risks of raloxifene by vertebral fracture status
Sontag, A., Wan, X., & Krege, J. H. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903427082 · Cited by 15
The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
Chen, L., Ning, G., Zhou, Z., Li, Y., Zhang, D., Wu, Q., Zhang, T., Cheng, L., & Feng, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123080 · Cited by 15
Ito, M., Tobinai, M., Yoshida, S., Hashimoto, J., & Nakamura, T. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0723-x · Cited by 15
Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture
Warriner, A. H., Outman, R. C., Saag, K. G., Berry, S. D., Colon-Emeric, C. S., Flood, K. L., Lyles, K. W., Tanner, S. B., Watts, N. B., & Curtis, J. R. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819bc1d3 · Cited by 14
Morden, N. E., Munson, J. C., Smith, J., MacKenzie, T. A., Liu, S. K., & Tosteson, A. N. A. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2925-9 · Cited by 14
Fitzpatrick, S. G., Stavropoulos, M. F., Bowers, L. M., Neuman, A. N., Hinkson, D. W., Green, J. G., Bhattacharyya, I., & Cohen, D. M. (2011) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2011.02.049 · Cited by 13
Oral Bisphosphonate Exposure and the Risk of Upper Gastrointestinal Cancers
Vogtmann, E., Corley, D. A., Almers, L. M., Cardwell, C. R., Murray, L., & Abnet, C. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140180 · Cited by 13
刘建立, 朱汉民, 黄琪仁, 张忠兰, 秦跃娟, 张颖, 魏道林, 陆敬辉, Liu, H., Liu, H., et al. (2004) · PubMed · Cited by 12
Campbell, I. A., Douglas, J., Francis, R. M., Prescott, R. J., & Reid, D. M. (2009) · Scottish Medical Journal · doi:10.1258/rsmsmj.54.1.21 · Cited by 11
Relationship of Bisphosphonate Therapy and Atrial Fibrillation/Flutter
Thadani, S. R., Ristow, B., Blackwell, T., Mehra, R., Stone, K. L., Marcus, G. M., Varosy, P. D., Cummings, S. R., & Cawthon, P. M. (2015) · CHEST Journal · doi:10.1016/j.chest.2015.11.022 · Cited by 11
Liu, J., Zhu, H.-M., Huang, Q., et al. (2004) · PubMed · Cited by 11
Zheng, S., Wu, Y., Zhang, Z., Yang, X., Hui, Y. H., Zhang, Y., Chen, S., Deng, W., Liu, H., Ekangaki, A., et al. (2003) · PubMed · Cited by 10
Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone
Villa, A., Castiglioni, S., Peretti, A., Omodei, M., Ferrieri, B. G., & Abati, S. (2011) · ISRN Rheumatology · doi:10.5402/2011/654027 · Cited by 9
Takeuchi, Y., Hamaya, E., Taketsuna, M., & Sowa, H. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000441 · Cited by 6 · cited 1×
“A study comparing postmarketing surveillance of raloxifene in younger women (aged < 75 y) versus older women (aged ≥75 y) showed no difference in overall adverse effects from raloxifene (351).”
BackgroundWright, E., Seed, P. T., Schofield, P., & Jones, R. H. (2010) · BMJ · doi:10.1136/bmj.c5315 · Cited by 4
Su1045 Bisphosphonate Use and the Risk of Colorectal Cancer: A Meta-Analysis
Andrici, J., Tio, M., & Eslick, G. D. (2013) · Gastroenterology · doi:10.1016/s0016-5085(13)61413-4 · Cited by 2
IOF Regionals – 4th Asia-Pacific Osteoporosis Meeting: Satellite Symposia
(2013) · Osteoporosis International · doi:10.1007/s00198-013-2539-7 · Cited by 1
Discontinuing denosumab treatment does not increase fracture risk
(2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.3 · Cited by 1
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Wu, A.-M., Bisignano, C., James, S. L., Abady, G. G., Abedi, A., Abu-Gharbieh, E., Alhassan, R. K., Alipour, V., Arabloo, J., Asaad, M., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00172-0 · Cited by 1,291
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Osteoporosis: A Review of Treatment Options.
Tu, K. N., Lie, J. D., Wan, C. K. V., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K., & Hyun, D. (2018) · PubMed · Cited by 735
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.